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ABSTRACT 21 
Bacillus subtilis is known as an endospore- and biofilm-forming bacterium with 22 
probiotic properties. We have recently developed a method for displaying heterologous 23 
proteins on the surface of B. subtilis biofilms by introducing the coding sequences of the 24 
protein of interest into the bacterial genome to generate a fusion protein linked to the C-25 
terminus of the biofilm matrix protein TasA. Although B. subtilis is a regular component 26 
of the gut microflora, we constructed a series of recombinant B. subtilis strains that were 27 
tested for their ability to immunize dogs following oral application of the spores. 28 
Specifically, we tested recombinant spores of B. subtilis carrying either the fluorescent 29 
protein mCherry or else selected antigenic peptides (tropomyosin and paramyosin) from 30 
Echinococcus granulosus, a zoonotic intestinal tapeworm of dogs and other carnivores. 31 
The application of the recombinant B. subtilis spores led to the colonization of the gut 32 
with recombinant B. subtilis but did not cause any adverse effect on the health of the 33 
animals. As measured by ELISA and immunoblot, the dogs were able to develop a 34 
humoral immune response against mCherry as well as against E. granulosus antigenic 35 
peptides. Interestingly, the sera of dogs obtained from immunization with recombinant 36 
spores of E. granulosus peptides were able to recognize E. granulosus protoscoleces, 37 
which represent the infective form of the head of the tapeworms. These results represent 38 
an essential step towards the establishment of B. subtilis as an enteric vaccine agent. 39 
  40 
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INTRODUCTION 41 
 The enteric immunization of mammalian species, including canids, is notably 42 
challenging. In the particular case of dogs, oral vaccines against parvovirus (1, 2), rabies 43 
(3) or canine infectious respiratory disease (4, 5) are both based on live attenuated 44 
organisms (virus and bacteria, respectively). Nevertheless, an environmentally safe 45 
method of immunization for the delivery of antigens that prevents the shed of the live 46 
attenuated pathogen has not been yet established in dogs. Several attempts of carriers for 47 
enteric antigens based on a viral or bacterial background have been developed recently, 48 
unfortunately with only moderate success (6-9). Bacillus subtilis is a well described and 49 
versatile microorganism, able to form endospores, develop into biofilms and even used as 50 
a probiotic in humans or livestock (10-12). We recently engineered B. subtilis for the 51 
display of heterologous proteins on the surface of the biofilm. To this end, the matrix 52 
protein TasA was fused to various peptides on its C-terminus, and the fusions were 53 
expressed in biofilm-inducing conditions (13). To optimize expression, we used the 54 
genetic background tasA/sinR. On one hand, SinR is a repressor of the tapA-sipW-tasA 55 
operon and other genes. Therefore, the sinR mutant resulted in enhanced expression 56 
levels of the fusion protein. On the other hand, the tasA mutant background would 57 
prevent competition of the endogenous TasA with the fusion protein (14, 15). 58 
An interesting pathogen is the zoonotic canine intestinal cestode Echinococcus 59 
granulosus sensu lato (16) responsible for causing cystic echinococcosis (CE) in 60 
mammalian and marsupial intermediate hosts, but also in humans as accidental hosts. The 61 
worldwide-distributed CE (17) is considered one of the most important neglected tropical 62 
diseases (18). Thus, CE is responsible for high human morbidity and mortality and is also 63 
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responsible for significant economic losses in livestock (19). The E. granulosus life cycle 64 
includes canids (mainly domestic dogs) as definitive hosts, which become infected by 65 
ingesting lungs or livers of intermediate hosts rich in Echinococcus cysts containing 66 
protoscoleces. Once the protoscoleces get in close contact with the intestinal mucosa of 67 
dogs, they develop into the parasitic form, i.e., 5-7 mm long, egg-producing tapeworms 68 
(16). The eggs of E. granulosus are shed in the feces of the definitive host by either the 69 
release of the last proglottid in the intestine or the direct excretion of the tapeworms. 70 
Intake of these tapeworm eggs by intermediate or susceptible accidental hosts then 71 
initiates a new round in the parasite’s life cycle. Since dogs are the main host and they 72 
spread disease by excreting parasite eggs in their feces, control programs are required that 73 
include regular deworming of the dog population (20). A vaccine for immunologically 74 
attack the egg-producing tapeworm might greatly help in reducing the risk of disease for 75 
humans. In previous studies, two potential antigens were proposed as vaccine targets 76 
against E. granulosus intestinal infections, namely the proteins tropomyosin (EgTrp) and 77 
paramyosin (EgA31) (21-24). 78 
 In the present study, we investigated the ability of recombinant B. subtilis 79 
to induce an antibody response in dogs upon oral application of spores containing TasA 80 
linked to mCherry or E. granulosus peptides (EgTrp and EgA31). 81 
 82 
RESULTS 83 
The intestinal microflora of dogs contains B. subtilis. In a first instance, we wondered 84 
if the intestinal microflora of dogs could be disturbed by the presence of exogenous B. 85 
subtilis. To answer this question, we first investigated whether B. subtilis was part of the 86 
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intestinal microflora in healthy dogs. For this purpose, feces were collected from either 87 
the University of Zurich (UZH) dog’s facility or from privately owned dogs. Each fecal 88 
sample was processed as indicated in the scheme depicted in Figure 1A. Our data imply 89 
that all the isolated bacteria that were able to sporulate and form biofilms in MSgg semi-90 
solid media belonged to Bacillus spp. (Figure 1B and C). Additionally, the isolated 91 
bacteria did not show a significant genetic divergence (Figure 1B) from the B. subtilis 92 
non-domesticated strain, NCIB 3610. Interestingly, we could also find close relatives as B. 93 
vallismortis and B. aerophilus. Taken together, our data indicate that B. subtilis is 94 
ubiquitous in the intestinal microflora of healthy dogs and that it is likely that the non-95 
domesticated B. subtilis NCIB 3610 will not significantly disturb the balance of the 96 
intestinal microflora. 97 
Luminescent B. subtilis bacteria could be detected in the dog gut. We next wondered 98 
whether recombinant spores of B. subtilis could germinate in the gut of dogs and display 99 
an antigen of interest. For this purpose, we incorporated the luxCDABE operon from 100 
Photohabdus luminescens (25), driven by a tapA promoter in a B. subtilis tasA/sinR strain 101 
harbouring also the tapA-sipW-tasA-mCherry operon (Table 1), generating the B. subtilis 102 
tasA/sinR/lux/TasA-mCherry strain. The genetic background tasA/sinR in B. subtilis 103 
improves the expression of heterologous genes driven by the tapA promoter (13). We 104 
hypothesized that this newly engineered strain would permit the easy tracking of B. 105 
subtilis by luminescence when in a vegetative state. As expected, an enhanced 106 
bioluminescence was observed when comparing the expression of B. subtilis luxCDABE 107 
(wt/lux) with that of B. subtilis tasA/sinR/lux/TasA-mCherry biofilms at 24, 48 and 72 h 108 
post-inoculation (Figure 2A). As observed in Figure 2B, such enhancement in 109 
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luminescence expression was also improved when the biofilms were incubated at 37˚C 110 
instead of 30˚C. Interestingly, already at 24 h post-inoculation, the expression of B. 111 
subtilis tasA/sinR/lux/TasA-mCherry was significantly increased when incubated at 37˚C 112 
rather than at 30˚C. Consistent with our previous research (13), the sporulation ability of 113 
B. subtilis tasA/sinR/lux/TasA-mCherry strain was decreased compared to B. subtilis 114 
wt/lux when growing at either 30˚C or 37˚C (Figure 2C). As depicted in Figure 2D 115 
(upper panel), no luminescence was detected in B. subtilis tasA/sinR/lux/TasA-mCherry 116 
endospores when diluted in milk, possibly since the tapA promoter is not active in the 117 
endospores. Milk was used as the media for the oral application of recombinant B. 118 
subtilis spores to dogs. Instead, vegetative cells (germinated from the same spore aliquot) 119 
were luminescent (Figure 2D, lower panel). The switch from non-luminescence in 120 
spores to luminescence in vegetative cells will permit to easily track the germination in 121 
vivo of the recombinant B. subtilis tasA/sinR/lux/TasA-mCherry spores by using an in 122 
vivo imaging system (IVIS) equipment.  123 
As a proof of principle, we used oral application to inoculate spores from B. 124 
subtilis tasA/sinR/lux/TasA-mCherry into two-weeks old puppies (Table 2, dogs #1 and 125 
#2). First, we followed the spores shedding in the puppies’ feces during three days (24, 126 
48 and 72 hpa (hours post-application)). For the detection of the recombinant spores, 127 
germinated spores in selective LB semi-solid media were initially monitored for 128 
luminescence expression. As observed in Figure 2E, the bacterial luminescence was 129 
detected at 48 hpa in puppy #2 and 72 hpa in both puppies. As the gastrointestinal transit 130 
in puppies is close to 24 h (26), our data suggest that the spores were retained in the gut 131 
of the animals, and a small fraction was shed three days after (72 hpa). 132 
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We next explored whether puppies could elicit a humoral immune response 133 
against the TasA-mCherry fusion. For this purpose, we provided the dogs with 134 
recombinant spores of the B. subtilis tasA/sinR/lux/TasA-mCherry strain on days 21 and 135 
42 after the first application. Interestingly, the dogs elicited a specific humoral immune 136 
response of both types IgG and IgA against the two tested recombinant proteins (H6-137 
mCherry (Figure S1, A, and C) and H6-TasA (Figure S1, B, and D). At day 60, the 138 
different intestinal sections (duodenum, jejunum, ileum/cecum, and colon) were 139 
inspected for luminescence using an IVIS equipment (Figure 2F). The monitoring of the 140 
opened intestine sections evidenced luminescence mainly in the jejunum, ileum/cecum, 141 
and colon but not in the duodenum. Consistent with this observation, we could also 142 
determine the presence of our recombinant bacteria by immunohistochemistry against 143 
TasA (anti-TasA) and mCherry (anti-dsRed2) (Figure S1E). Our results indicate that 144 
recombinant spores of B. subtilis tasA/sinR/lux/TasA-mCherry can germinate in the gut 145 
and get established in the intestinal microflora, permitting the heterologous expression of 146 
both Lux and TasA-mCherry proteins. 147 
Recombinant spores of B. subtilis induce a specific humoral response against 148 
TasA-mCherry in dogs. We next administrated dogs with recombinant spores of B. 149 
subtilis by starting the applications in nine-weeks-old animals, which is in agreement 150 
with the Swiss schedule for dog's vaccination. To this end, we included three dogs in our 151 
experiments, separated in one group of two dogs (Table 2, dogs #4 and #5) orally applied 152 
with recombinant B. subtilis tasA/sinR/lux/TasA-mCherry spores and a second group 153 
composed by a single dog, orally applied with milk (placebo) (Table 2, dog #3). The 154 
animals received three doses of recombinant B. subtilis spores on days 1, 21 and 42. The 155 
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elicitation of a systemic humoral immune response against the fusion TasA-mCherry was 156 
monitored by indirect ELISA using weekly-collected sera samples. Only dogs orally 157 
applied with recombinant B. subtilis spores were able to elicit a specific humoral immune 158 
response against H6-mCherry (Figures 3A and S2A). This response was more 159 
pronounced for the dog #4 (grey bars). Remarkably, this humoral immune response 160 
consists of IgG but not of IgA isotype (Figure S2A) In contrast, indirect ELISA against 161 
the non-related antigen glutathione S-transferase (GST) did not show any measurable 162 
response from the dog’s sera, either for IgG or IgA antibody isotypes (Figure 3B and 163 
Figure S2B). Consistent with our data, we could also observe a specific H6-mCherry 164 
humoral immune response by immunoblotting. Indeed, we also found an antibody 165 
response of IgG isotype (Figure 3D) and not of IgA isotype (Figure S2D) when 166 
checking for sera at day 60. Interestingly, we could observe that all the tested animals 167 
(inoculated with recombinant B. subtilis spores or placebo) were able to respond against 168 
H6-TasA protein for both antibody isotypes, IgA and IgG (Figure 3C and Figure S2C). 169 
We further investigated if the recombinant spores get shed in dog’s feces after 170 
each application. For this purpose, anal swabs were collected daily up to six days post-171 
application after the first and second oral application (on days 1 and 21) of recombinant B. 172 
subtilis spores (Table 3), cultivated on selective solid media, and the grown colonies 173 
were later examined in an IVIS imaging system for the detection of luxCDABE operon 174 
luminescence. Only dog #4 shed recombinant spores on the second day after the first and 175 
second oral application. For the third oral application of recombinant B. subtilis spores 176 
(Table 4), feces were collected daily in a random manner since the Swiss animal 177 
experimental rules prohibit separate caging of dogs. Under these conditions, three random 178 
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samples (RS) were collected daily during three days post-application. The presence of 179 
recombinant B. subtilis spores in feces was confirmed by germination in selective LB 180 
semi-solid media, followed by luxCDABE luminescence detection and further 181 
quantification of the positive colonies. Our data shows that RS feces contain spores on 182 
days 1 to 3 following the third oral application. Interestingly, and consistent with our 183 
experimentation schedule, only two feces samples contained recombinant B. subtilis 184 
spores on day 1 (RS1 and RS2) and day 2 (RS1 and RS3) suggesting that these samples 185 
were from the two dogs of the recombinant B. subtilis spore group. Then on day 3, 186 
however, only one feces sample contained recombinant B. subtilis spores (RS2). On day 187 
60 (Figure 3F), different intestinal sections were inspected, and inflammatory cells were 188 
not found either in placebo or in dogs orally inoculated with the recombinant B. subtilis 189 
spores. This result indicates that the recombinant B. subtilis spores, or the vegetative cells, 190 
do not have any detrimental effect on the intestinal structures. This finding is consistent 191 
with the probiotic abilities of B. subtilis (27). Collectively, our data show that dogs orally 192 
applied with recombinant B. subtilis tasA/sinR/lux/TasA-mCherry spores can elicit a 193 
specific humoral response against the TasA-mCherry fusion.  194 
Induction of intestinal immunity in dogs against E. granulosus antigens. Next, we 195 
wondered whether a specific humoral immune response against the integumental antigens 196 
from the parasite E. granulosus (EgTrp and EgA31) could be elicited by using the 197 
immunization methodology described above. For this purpose, we used two different 198 
recombinant B. subtilis spores, engineered to express the fusion proteins TasA-(102-207) 199 
EgTrp or TasA-(370-583)EgA31 (Table 1 and (13)). For simplification, we hereafter 200 
refer to these as B. subtilis TasA-EgTrp and B. subtilis TasA-EgA31. As described by 201 
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Vogt et al., 2016 (13), these strains can display the E. granulosus antigenic peptides 202 
(EgTrp and EgA31) fused in frame to the C-terminus of TasA on the surface of in vitro 203 
biofilms. For this experiment, four groups of two dogs each (Table 2) were employed. 204 
Three groups were orally applied on days 1, 21 and 42 with recombinant B. subtilis 205 
spores harbouring fusions of TasA-EgTrp (group EgTrp), TasA-EgA31 (group EgA31) 206 
and a mixture of both recombinant spores (TasA-Egtrp and TasA-EgA31) (group 207 
mixture). The fourth group was the placebo control, which received only milk. The 208 
animals were nine weeks old when they received the first oral application. In agreement 209 
with our previous results, no variations in the body weight between of all the 210 
experimental groups were observed during the whole procedure (Figure S3A). The 211 
elicitation of the humoral response for the TasA fused to E. granulosus antigens was 212 
monitored weekly from collected sera of the treated dogs. For this purpose, an indirect 213 
ELISA was developed for the detection of specific antibodies against the purified 214 
proteins H6-EgTrp, H6-EgA31, H6-TasA and the non-related antigen H6-mCherry. Of 215 
note, maternal antibodies can be detected in young dogs as an early signal (7-15 days 216 
post-immunization) in ELISA (28) and therefore, was considered as not significant. We 217 
noticed that at least one of the dogs in each of the groups receiving a single kind of 218 
recombinant B. subtilis spores showed to be positive for its respective antigen (dog#2 of 219 
group Tas-EgTrp (black bars) and dog#2 of group TasA-EgA31 (black bars)), when 220 
tested for specific IgG antibodies against H6-EgTrp (Figure 4A) and H6-EgA31 (Figure 221 
4B). However, the dogs that received the mixture of recombinant spores responded 222 
mainly to H6-EgA31, especially dog#2 (mixture group, black bars). Placebo dogs did not 223 
react to any of these two antigens (Figures 4 A and B). None of the animals responded 224 
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against the non-related H6-mCherry antigen (Figure 4C), showing the specific nature of 225 
the immune response mounted by the recombinant spores. Consistent with our previous 226 
result (Figure 3) all the animals presented a specific immune response against H6-TasA 227 
(Figure 4D). However, when testing the sera for specific IgA antibodies (Figures S3 B-228 
E) targeting H6-Egtrp, H6-EgA31, H6-mCherry, and H6-TasA, no immune response was 229 
detected for any of these antigens.  230 
We next questioned if the sera of the dogs collected on day 60 could also 231 
recognize the antigens in the parasite context. The two antigens used in this study, EgA31 232 
and EgTrp, have been described previously as localizing in the tegument and 233 
subtegument outer membranes of the E. granulosus protoscolex (23, 29, 30). For this 234 
purpose, immunohistochemistry was performed over E. granulosus protoscoleces by 235 
incubation with the dog sera. For the analysis of the data, we took particular 236 
consideration of the staining of the subtegument/tegument membranes, corresponding to 237 
the enlarged insets shown in Figure 4E. The brownish coloration observed in the internal 238 
regions of the protoscoleces by immunohistochemistry was considered as background 239 
because it is not possible to distinguish between incubation with placebo and spores-240 
treated sera. Our results reveal that the subtegument/tegument membranes presented 241 
brown coloration (inset, black arrowheads) when incubated with sera of dogs #2 of group 242 
EgTrp and group EgA31 and for both dogs of group mixture. In contrast, the sera of 243 
placebo dogs, dog #1 of the EgTrp group and dog #1 EgA31 group revealed a negative 244 
coloration (blue) of subtegument/tegument membranes of the protoscoleces. These data 245 
are consistent with the immune response observed by ELISA (Figures 4 A-D) and 246 
 o
n
 January 4, 2018 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://iai.asm
.org/
D
ow
nloaded from
 
 12 
 
strongly suggest that the dogs treated with recombinant B. subtilis spores harbouring E. 247 
granulosus antigens could recognize the parasite. 248 
In an attempt to re-isolate the applied recombinant B. subtilis from the gut of the 249 
treated animals, we recovered the intestinal microflora of duodenum, jejunum, and ileum 250 
of two dogs, which received the recombinant B. subtilis spore mixtures. The recombinant 251 
B. subtilis were isolated in selective media (Table 1). Interestingly, recombinant B. 252 
subtilis bacteria could be separated from both the duodenum and the jejunum of the dog 253 
#2, but no recombinant bacteria were isolated from the intestine of dog #1. The presence 254 
of recombinant bacteria was confirmed by PCR of colonies isolated from duodenum and 255 
jejunum of dog #2 from the mixture group (Figure 4F).  256 
Importantly, neither inflammatory nor degenerative lesions could be detected by 257 
histology in the intestinal sections. Likewise, no undesirable clinical signs were observed 258 
in the dogs after treatment with spores (Figure S3F). These data confirm that the use of 259 
recombinant spores from B. subtilis is safe for dogs. Our results indicate that oral 260 
application of recombinant B. subtilis spores harbouring TasA fusions to E. granulosus 261 
antigens (EgTrp and EgA31) get germinated in the gut and elicited a specific humoral 262 
response in dogs. 263 
 264 
DISCUSSION 265 
 Current evidence indicates that B. subtilis endospores can germinate in the gut of 266 
mice, rabbit, and humans (31, 32). Consequently, engineered B. subtilis spores may be 267 
used as carriers for the administration of antigens in the immunization against enteric 268 
pathogens such as viruses, bacteria, and parasites or even for the induction of tolerance in 269 
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the treatment of chronic inflammatory diseases (33). In this study, we provide evidence 270 
that oral application of recombinant B. subtilis spores in dogs resulted in spore 271 
germination in the gut. The presence of vegetative recombinant bacteria could favour the 272 
formation of an intestinal biofilm, allowing the stimulation of the gut-associated 273 
lymphoid tissue (GALT) (31), which elicited a humoral response against TasA fused to 274 
an epitope. In fact, our results show that a humoral immune reponse in dogs against the 275 
fusion protein TasA-mCherry, and tapeworm E. granulosus fusions TasA-EgTrp and 276 
TasA-EgA31 was mounted, suggesting spore germination and GALT stimulation by the 277 
recombinant B. subtilis spores. 278 
In contrast to other methodologies based on surface-expression or in surface-279 
adsorption of antigens on spores of B. subtilis (34), our approach consisted in the 280 
expression of heterologous peptides after spore germination. This method is particularly 281 
advantageous for oral application since the spores can bypass the stomach barrier without 282 
damaging the structure of the heterologous peptide. Another advantage of using B. 283 
subtilis as an antigen carrier is its probiotic nature (27, 35) that permits a safe application. 284 
We demonstrated that there was no significant difference in body weight of the dogs 285 
during the whole procedure as well as no undesirable clinical signs in the animals 286 
receiving recombinant B. subtilis spores. Hematoxylin/eosin-stained histological cuts 287 
from different intestinal sections showed neither inflammatory nor degenerative lesions 288 
after the oral application of the recombinant B. subtilis spores. The fact that B. subtilis, as 289 
showed here and by others (36, 37), is part of the dog’s natural intestinal microflora, 290 
reinforces the safety of this organism for its use in the delivery of antigens in the intestine. 291 
Altogether, our data show that B. subtilis can safely deliver heterologous peptides in the 292 
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intestine of dogs to subsequently mount an immune response. Interestingly, and in line 293 
with our results, the biofilm formation ability of B. subtilis strains isolated from intestinal 294 
microflora has also been described in species as diverse as grass carp (38) or human (39, 295 
40). It has been suggested that the biofilm-forming properties of B. subtilis strains are 296 
relevant for the growth and formation of biofilms in the intestine (32, 40). In this study, 297 
we used the non-domesticated B. subtilis NCIB 3610 strain to engineer recombinant 298 
spores. This strain has been extensively studied for its remarkable biofilm-forming 299 
abilities (15). Thus, the recombinant spores used in this study (Figure 2 and (13)) have 300 
the potential to germinate and then form a biofilm in the mucosa of the intestine. We 301 
present strong evidence indicating that recombinant B. subtilis colonize and express the 302 
heterologous proteins in the dog’s intestine as denoted by: i) the visualization of 303 
vegetative recombinant B. subtilis by luminescence (Figure 2F), immunohistochemistry 304 
against the specific antigens (Figure S1E) and specific PCR of perfused intestinal 305 
content (Figure 4F); ii) the quantification of recombinant B. subtilis spores shed in feces, 306 
which are in lower numbers than the initial load of spores suggesting an intestinal 307 
retention and germination of the spores (Tables 3 and 4). 308 
By using indirect ELISA and immunoblotting with dog sera, we demonstrated 309 
that dogs generated a humoral response against the presented antigens, mCherry or E. 310 
granulosus peptides. Interestingly, the tested dogs also developed a humoral response 311 
against TasA, which was also positive for placebo dogs in all the experimental settings. 312 
This result suggests that native TasA derived from the dog’s intestinal microflora could 313 
stimulate local immunity, which relates to the maturation of the intestinal microflora of 314 
the dogs. It has been proposed by others (41) that the generation of antibodies against the 315 
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intestinal microflora promotes the host-microbiota mutualism through a reduction of the 316 
inflammatory response towards the microbiota, allowing the immune exclusion of the 317 
bacteria in direct contact with the intestinal mucosa. 318 
Even if the humoral response recognizes the recombinant E. granulosus antigens 319 
EgA31 and EgTrp, further research will unveil whether this technology can neutralize 320 
parasitic infections. A good indication in this direction is the recognition of the tegument 321 
and subtegument from the isolated E. granulosus protoscoleces by the serum of the 322 
recombinant B. subtilis spores-treated dogs.  323 
Collectively, our results demonstrate that the oral application of recombinant B. 324 
subtilis spores elicited a specific humoral response in dogs. This technology could be the 325 
foundation for the development of vaccines for dogs that carry B. subtilis in their 326 
intestinal microbiota. 327 
 328 
MATERIALS AND METHODS 329 
Ethics statement. All the dog experiments were performed according to the guidelines of 330 
the animal experimentation law (SR 455.163; TVV) of the Swiss Federal Government. 331 
The Cantonal Veterinary Office of Zurich approved the protocols with the following 332 
animal experimentation number 100/2010.  333 
B. subtilis strains, media and culture conditions. A list with the B. subtilis strains used 334 
in this study is shown in Table 1. For routine growth and spore quantification, cells were 335 
propagated on Luria-Bertani (LB) medium. For biofilm assays, cells were scraped from 336 
overnight growth on LB-agar plates, resuspended in LB liquid medium to an OD600 nm of 337 
1, and then 2 μl of this suspension were spotted on MSgg solid medium (42). Biofilms 338 
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were incubated at 30°C or 37˚C. The final concentration of antibiotics used for the B. 339 
subtilis strains were the following: spectinomycin (Spc) (100 µg/ml), kanamycin (Km) 340 
(10 µg/ml), MLS: erythromycin (1 µg/ml) and lincomycin (25 µg/ml), and 341 
chloramphenicol (Cm) (5 µg/ml).  342 
Plasmid constructions. pQE80L-EgA31PstI/DraI was obtained from Dr. A-F. Pétavy 343 
(Université Claude Bernard Lyon 1, Lyon, France) (43). pQE32-(102-278)EgTrp was 344 
achieved by PCR amplification of (102-278)EgTrp fragments from the constructs pQIA-345 
EgTrp, kindly provided by Dr. Adriana Esteves (Universidad de la República, 346 
Montevideo, Uruguay) (21) using specific primers containing flanking BamHI and PstI 347 
restriction sites followed by ligation between BamHI and PstI in pQE-32 (QIAGEN). 348 
pQE32-mCherry was obtained by PCR amplification of mCherry from pRSET-mCherry 349 
(44) using specific primers containing BamHI and HindIII restriction sites followed by 350 
ligation between BamHI and HindIII in pQE-32 (QIAGEN). pET22b-TasA (45) was 351 
provided by Dr. Diego Romero (University of Malaga, Spain). pDR-PtapA-luxCDABE was 352 
obtained by PCR amplification of luxABE genes from pSB403 (25) using specific primers 353 
containing AgeI and SacI restriction sites, followed by ligation between AgeI and SacI in 354 
pDR183-PtapA/luxA. The plasmid pDR183-PtapA/luxA was obtained by PCR amplification 355 
of luxCDA genes from pSB403 using specific primers to insert at the 5’ end an EcoRI 356 
restriction site followed by RBS (ribosome binding site) and at the 3’ end AgeI/SacI 357 
restriction sites. The PCR fragment was ligated between EcoRI and SacI in pDR183-PtapA. 358 
The plasmid pDR183-PtapA was obtained by PCR amplification of PtapA from pBS-359 
TapAop-mCherry (13) using specific primers containing SacII and EcoRI restriction sites, 360 
followed by ligation between SacII and EcoRI in pDR183 [lacA:: erm] (46) (kindly 361 
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provided by Dr. David Rudner, Harvard University, MA, USA). All oligonucleotides 362 
were obtained from Microsynth AG, Switzerland and described in Table S1. 363 
Antibodies and reagents Rabbit polyclonal anti-TasA was a gift from Dr. R. Losick 364 
(Harvard University, Cambridge, USA). Mouse polyclonal anti-EgTrp and mouse 365 
polyclonal anti-EgA31 were a gift from Dr. M-F. Pétavy (Université Claude Bernard 366 
Lyon 1, Lyon, France). Goat anti-GST was purchased from GE Healthcare Life Sciences. 367 
Mouse anti-dsRed2 was purchased from Santa Cruz Biotechnology, USA. Rabbit F(ab')2 368 
anti-dog IgG H&L-peroxidase was acquired from Abcam. Goat anti-dog IgA antibody-369 
peroxidase was obtained from Bethyl Laboratories, Inc. (Montgomery, TX, USA). Rabbit 370 
anti-goat IgG (whole molecule)-peroxidase and Goat anti-mouse IgG(Fab)'-peroxidase 371 
were obtained from Sigma-Aldrich. Isopropyl-ß-D-thiogalactopyranoside (IPTG) was 372 
acquired from Biosolve Chimie, France. 373 
Transformation of B. subtilis. Bacillus subtilis strain 168 was transformed as described 374 
previously by Cutting and Vander Horn (47). The transformants were selected with the 375 
appropriate antibiotics for a double crossover recombination at the amyE locus or lacA 376 
locus (48). The different operons were then transferred to undomesticated B. subtilis 377 
NCIB 3610 strain by SPP1-mediated generalized transduction (49). The positive clones 378 
were identified by direct PCR of the selected colonies using specific primers.  379 
Characterization and identification of B. subtilis in the dog intestinal microflora. 380 
Feces were analyzed from seven samples (21 dogs) of dogs from the UZH animal facility 381 
and nine individual samples collected from privately owned dogs. All the samples were 382 
from healthy animals that had not been treated for at least one year with antibiotics or 383 
probiotics. The feces were resuspended in ten times weight volume with PBS, serially 384 
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diluted, plated in LB (Luria-Bertani) agar media and incubated for two days at 37˚C. The 385 
isolated colonies were streaked in Difco sporulation agar media for 24 h at 37˚C and 386 
selected for rod shape by microscope inspection using a 63X lens. Then, the selected 387 
isolates were re-inoculated in 3 ml of Difco sporulation media, incubated on an orbital 388 
shaker for four days at 37˚C and inspected at the microscope for the presence of 389 
endospores. The selected sporulating rod bacteria were stored at -80˚C in 15% glycerol 390 
for further analysis. The sequence of the rrnE gene of 16S was analyzed as described by 391 
Hoa et al., 2000 (50). Briefly, PCR amplification was performed using primers specific 392 
for B. subtilis rrnE gene of the 16S rRNA (P1, 5'-GCGGCGTGCCTAATACATGC-3' 393 
and P2, 5'-CACCTTCCGATACGGCTACC-3') and then sequenced by the Sanger 394 
method at Microsynth, AG, Switzerland. Sequences were aligned with CLUSTALX (51). 395 
The optimal model of DNA evolution was evaluated for best fit of the dataset using 396 
MRAIC (Nylander, J. A. A. 2004. MrAIC.pl. Program distributed by the author; 397 
Evolutionary Biology Centre, Uppsala University). Bayesian phylogeny was inferred 398 
using BEAST (version 1.5.3). Markov Chain Monte Carlo simulation with GTR 399 
substitution matrix and a strict clock was run over 10'000'000 generations. The tree files 400 
were combined into one consensus tree by using LOGCOMBINER. The consensus tree 401 
was displayed with FIGTREE (52), representing the similarities between the 16S rRNA 402 
genes. The rrnE gene sequence from undomesticated B. subtilis NCIB 3610 strain was 403 
used as a reference. A list of the assigned bacteria strain from the isolated clones is 404 
provided in Table S2. 405 
Quantification of spores in a biofilm. The ability of recombinant B. subtilis to sporulate 406 
in a biofilm was determined as described by Vlamakis et al. (15). Briefly, B. subtilis 407 
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cultured in LB media was diluted to an OD600 nm of 1; and 10 μl of the suspension was 408 
inoculated in duplicate over 2.5 ml of MSgg medium in 12-well culture plates. The 409 
culture plates were incubated at room temperature with no agitation. Samples of cells 410 
were taken after 48 h and subjected to mild sonication conditions (10 s at 14 kHz) to 411 
obtain intact single cells. After sonication, each preparation was normalized to OD600 nm 412 
of 1, incubated for 20 min at 80 °C to kill vegetative cells and serially diluted to 413 
determine viable spore counts in selective LB-agar plates. 414 
Production of recombinant B. subtilis spores. The recombinant spores were produced 415 
and purified as described by Vogt et al., 2016 (13). A list of the B. subtilis strains used in 416 
this study is provided in Table 1. 417 
Expression and purification of Hisx6 tagged proteins. pQE31-mCherry, pQE32-(102-418 
278)EgTrp and pQE80L-EgA31PstI/DraI were expressed in Escherichia coli (E. coli) 419 
M15[pREP4] (Qiagen). pET22b-TasA was expressed in E. coli BL21 (New England 420 
BioLabs, Inc). The culture was induced with isopropyl β-D-thiogalactoside (1 mM), 421 
grown for 4h, and centrifuged at 3,500 rpm for 15 min. The pellet was resuspended in 6 422 
ml of PBS and incubated for 15 min on ice with 0.1 mg/ml lysozyme, 5 mM DTT, 1.5% 423 
lauryl sarcosine and cOmplete™ protease inhibitor cocktail (Roche, Switzerland). The 424 
lysate was sonicated (six times for 10 s each) and centrifuged at 12,000 x g for 15 min. 425 
The supernatant was supplemented with 1% Triton X-100 and loaded onto a Ni 426 
Sepharose 6 Fast Flow (GE Healthcare), previously equilibrated with five volumes of 20 427 
mM imidazole in 50 mM NaH2PO4, for 2h at 4˚C in a rotation wheel. Subsequently, the 428 
resin was washed with 10 volumes of 60 mM imidazole, 200 mM NaCl, 0.1% Triton X-429 
100 and 50 mM NaH2PO4, then with 10 volumes of 60 mM imidazole, 300 mM NaCl, 430 
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0.1% Triton X-100 and 50 mM NaH2PO4 and finally with 10 volumes of 60 mM 431 
imidazole, 400 mM NaCl, 0.1% Triton X-100 and 50 mM NaH2PO4. The protein was 432 
eluted four times by incubating 10 min each with 250 µl of 250 mM imidazole, 400 mM 433 
NaCl, 0.1% Triton X-100, and 50 mM NaH2PO4. 434 
The GST protein was expressed from pGEX-6P-1 (GE Healthcare) in E. coli 435 
BL21 and purified following the instructions provided by the manufacturer. 436 
The eluted proteins were pooled in a single fraction and stored at 4˚C in 30% 437 
glycerol. The protein concentration was obtained by comparison to a BSA calibration 438 
curve in SDS-polyacrylamide gel followed by Coomassie blue staining. The estimation of 439 
the protein concentration was performed by densitometry using the gels algorithm from 440 
ImageJ 1.48v software (Wayne Rasband, NIH, USA). 441 
Biofilm Imaging. Whole colonies were photographed, and the images were processed as 442 
described by Vogt et al., 2016 (13).  443 
Experimental administration of recombinant B. subtilis spores in dogs. In the 444 
Vetsuisse animal facility of the University of Zurich, 2-4 beagle dogs were housed in 445 
pens of a surface of 1.45 m x 4.5 m with access to an outside area of 1.45 m x 5.5 m. Also, 446 
pens were enriched with installations permitting dogs to play in a three-dimensional 447 
space, to rest and to retreat. Beagle dogs were raised for laboratory use in the Vetsuisse 448 
animal facility of the University of Zurich. All the dogs were vaccinated against 449 
leptospirosis, canine distemper, canine hepatitis, parvovirus infection and parainfluenza 450 
viruses (Canigen L, Virbac, and Canigen, SHA2PPi). The dogs were orally applied three 451 
times on days 1, 21 and 42 with 5 x 10
10
 CFU per dose of recombinant B. subtilis spores. 452 
Each dose of the recombinant B. subtilis spores was diluted in 1 ml of cat milk 453 
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(Whiskas® Mars, Virginia USA) to increase palatability. The placebo group received 1 454 
ml of cat milk. Each oral gavage was performed in morning hours after feeding the dogs. 455 
All the animals were clinically monitored in weekly routine and every day after each oral 456 
administration. Data on the animal number assigned, sex, age, and kind of recombinant B. 457 
subtilis spore applied to each dog are provided in Table 2. Blood samples (6 to 8 ml) 458 
were collected from cephalic vein weekly, starting one day before the first oral gavage. 459 
The serum was used to test humoral response against purified E. coli recombinant 460 
proteins. 461 
Animal necropsy. The dogs were sacrificed with an intravenous administration of 462 
acepromazine 0.1 ml/10 kg (Prequillan™, AROVET AG, Switzerland) followed by three 463 
doses of 80 mg/kg of sodium pentobarbitone (Esconarkon, Streuli Pharma AG, 464 
Switzerland). During the post-mortem examination blood sample, feces and intestinal 465 
sections were collected. 466 
Immunoblotting. Identical amounts of purified recombinant protein (3 µg) were mixed 467 
with sample buffer (8 % SDS, 40 % Glycerol, 200 mM Tris pH 6.8, 4 % 2-468 
mercaptoethanol, 0.4 % Bromophenol blue), heated for 5 min at 95˚C and loaded 469 
consecutively in a 12% SDS-polyacrylamide gel. After migration, the proteins were 470 
transferred to an Amersham™ Protan™ 0.45 µm nitrocellulose blotting membrane (GE 471 
Healthcare) and lanes were cut into stripes. The stripes were incubated in dogs sera 472 
diluted (1:100) in 5% milk-PBS. Samples were further processed as described by Glück 473 
et al. (53). 474 
Indirect ELISA. Recombinant purified protein (500 ng/well) in 0.2 M bicarbonate buffer 475 
pH 9.4 was coated for 16 h at 4˚C in a 96 well multi-well plates (Nunc-Immuno Maxisorp, 476 
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ThermoScientific). Sample wells were incubated for 2 h at room temperature with 477 
blocking buffer (5% milk, 0.1% Tween-20 in PBS). The dog's sera were diluted to 1:500 478 
in blocking buffer, added 50µl per well and incubated overnight at 4˚C. Samples were 479 
incubated with the corresponding secondary anti-dogs antibody conjugated to HRP 480 
diluted in blocking buffer for 1 h at 37˚C in a moist chamber. Between each incubation, 481 
the plates were washed three times with PBS containing 0.05% Tween-20. The ELISA 482 
was developed by the addition of 100 µl per well of TMB substrate (ThermoFisher 483 
Scientific) in the dark for 30 min at room temperature, and the reaction was stopped by 484 
adding 100µl 1M H2SO4. The plate’s absorbance was read at OD450 nm using an SLT 340 485 
ATTC Tecan microplate reader (Tecan US Inc.). The data were analyzed and processed 486 
using Microsoft®Excel® for Mac 2011. The cut-off was determined as the average of 487 
three negative controls. The negative control value was obtained by incubation of the 488 
antigen only with the secondary antibody conjugated to HRP. The cut-off was subtracted 489 
from all the sample values. Each value has been subtracted to its corresponding pre-490 
immune value (PI). 491 
Histology and immunohistochemistry. The dog's intestines were sectioned in 492 
duodenum, jejunum, ileum, cecum, and colon. Each intestinal section was knotted in both 493 
ends previous to sectioning to avoid the loss of the intestinal content. The samples of 494 
approximately 2 cm length were fixed in 4% formaldehyde. After fixation, each sample 495 
was dehydrated in alcohol solutions of increasing concentration and embedded in paraffin. 496 
The embedded samples were cut at 2-3 µm thick slides and stained with hematoxylin and 497 
eosin (HE).  498 
For immunohistochemistry of the dog’s intestinal section, the samples were de-499 
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paraffinized, rehydrated and incubated for 30 min at room temperature with the primary 500 
antibody (rabbit anti-TasA serum or mouse anti-dsRed2 serum). A detection kit, 501 
containing the secondary antibody and aminoethyl carbazole (AEC) as chromogen, was 502 
subsequently applied according to the manufacturer’s protocols (Peroxidase/AEC 503 
Rabbit/Mouse Kit, DAKO). 504 
E. granulosus protoscoleces were isolated from a sheep liver cyst. The samples 505 
were treated for immunohistochemistry by fixing, embedding in paraffin and de-506 
paraffinizing as described above. Subsequently, the samples in EDTA buffer pH 9.0 (1.25 507 
mM EDTA, 10mM Tris pH 9.0) were heated using a steamer (Pascal, Dako Cytomation) 508 
for 20 min at 98˚C. The slides were blocked for 10 min at room temperature with 509 
Peroxidase-Blocking Solution, Dako REAL (#S2023, DAKO). The samples were then 510 
incubated with the indicated dog serum (diluted 1:50) followed by a rabbit F(ab’)2 anti-511 
dog IgG (H&L) conjugated to HRP (1:100, ab136759, Abcam), stained with liquid 512 
DAB+ substrate chromogen system (brown, DAKO) and counterstained with 513 
hematoxylin (blue). 514 
Images were acquired using light microscope Olympus CX41 equipped with a 40 515 
X objective lens and Olympus Vanox-S AxioCam interface. The acquired images were 516 
processed using Image J software (Wayne Rasband, NIH, USA. http://imagej.nih.gov/ij). 517 
Detection of recombinant spores in intestinal content The small intestine was 518 
dissected in duodenum, jejunum, and ileum. Perfusion collected the intestinal content of 519 
each section with vigorous flushes of PBS, centrifuged at 14,000 x g and 20°C for 15 min. 520 
The pellet was resuspended in 20 ml PBS and centrifuged at 1,500 x g for 10 min at 20˚C. 521 
The supernatant was collected, centrifuged at 14,000 x g for 15 min and 20˚C and the 522 
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final pellet was resuspended in 3 ml of PBS. Serial dilutions prepared from 1x10
-1
 to 523 
1x10
-6
, and 10 µl of each dilution plated on semi-solid LB-kanamycin plates (10 µg/ml) 524 
and incubated for 36 h at 37°C. The colonies were counted, and the amount of CFU/ml 525 
was estimated (15). 526 
Colony PCR. A colony was resuspended in 15 µl lysis buffer (50 mM KCl, 0.1 % Tween 527 
20, 10 mM Tris-HCl pH 8.3) and heated to 99°C for 10 min. The PCR amplicons were 528 
obtained by thermocycling 5 µl of bacterial lysate with 15 µl of PCR master mix (0.2 mM 529 
dNTPs, 150 ng of each forward and reverse primers, 0.3 µl Taq DNA polymerase (5U/µl, 530 
New England Biolabs, Inc.), 1µl DMSO). The following internal primers were used for 531 
detection B. subtilis recombinant strains; for Egtrp 5’-ATGCG 532 
CGGCCGCCATTATGATGGCAATGAAATTG-3’ and 5’-GATCCCCGGG 533 
GGGATCCTTACTCTTGCTCGGAGACTTCGAG-3’, and for EgA31 5'-ATGCGC 534 
GGCCGCCGCAGCTGAAAAACAAGCCATG-3' and 5'-GATCCCCGGGGGA 535 
TCCTCACCTTGTTTCAAGCATTTCAAT-3'. The PCR amplicons were monitored by 536 
agarose gel electrophoresis. Images were acquired using Molecular Imager® Gel Doc™ XR 537 
with an incorporated Image Lab™ Software (Bio-Rad) and processed using Image J 1.48v software 538 
(W. Rasband, NIH, USA) and Microsoft Powerpoint for Mac 2011. 539 
IVIS. The luminescence of biofilm and intestinal samples were acquired using a Xenogen 540 
IVIS™100 Imaging System (Imaging Technologies) equipped with a CDD array 541 
scientific camera (Spectral Instruments, Inc.), mounted over light-tight specimen chamber, 542 
a 600 series camera controller and a camera cooling system. The images were analyzed 543 
and processed using a Living Image, version 4.0 software (Caliper Life Sciences, Inc). 544 
 545 
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 728 
FIGURES LEGENDS 729 
Figure 1. Bacillus subtilis is present in the dog's intestinal microflora. A) Schematic 730 
representation of the procedure used to sequence the 16S rrnE gene from sporulating 731 
bacteria isolated from feces of dogs of the UZH animal facility and privately owned dogs. 732 
B) Baysian phylogeny of the 16S rrnE gene isolated from sporulating bacteria isolated 733 
from privately owned and UZH facility dog’s feces samples. Sequences are compared 734 
with the reference sequence obtained from undomesticated B. subtilis NCIB 3610 (top). 735 
Alignment gaps and missing data were eliminated in pairwise sequence comparisons. Bar, 736 
0.0030 changes per nucleotide position. C) Colony top view of bacterial clones isolated 737 
from dogs feces of the UZH animal facility. Bacteria were growth over MSgg solid media 738 
for 72 h at 30˚C. The assigned bacteria clone numbers are denoted at each picture up-left 739 
corner. Scale bar is 1 cm. 740 
Figure 2. Tracking of luminescent Bacillus subtilis in the gut of dogs. A) Top view of 741 
luminescent biofilms from B. subtilis strains wt/lux, and tasA/sinR/lux/TasA-mCherry 742 
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incubated in MSgg semi-solid media for 24, 48, and 72h at 30˚C. A color luminescence 743 
scale is shown for each row. The scale bar is 1 cm. B) Comparison of luminescence of B. 744 
subtilis wt/lux (gray bars) and tasA/sinR/lux/TasA-mCherry (white bars) biofilms at 30˚C 745 
and 37˚C when incubated for 24, 48 and 72h. The data represent the mean ± SEM (t-test, 746 
** p<0.01, n=4). C) Sporulation ability of B. subtilis wt/lux, and tasA/sinR/lux/TasA-747 
mCherry of 72h biofilms when incubated at 30˚C and 37˚C. The data represent the mean 748 
± SEM (t-test, * p<0.05 and ** p<0.01, n=4). D) Comparison of the luminescence of 749 
spores resuspended in milk (upper panel) and vegetative cells (lower panel) from B. 750 
subtilis tasA/sinR/lux/TasA-mCherry strain. A color luminescence scale is shown for each 751 
panel. E) Germination of spores isolated from anal swabs of dogs #1 and #2 after the first 752 
oral application of the B. subtilis tasA/sinR/lux/TasA-mCherry spores. Anal swabs 753 
samples were collected at 48 and 72 hpa. The spores were incubated in selective LB 754 
semi-solid medium and monitored for luminescence of vegetative cells. F) Detection of 755 
luminescence from B. subtilis tasA/sinR/lux/TasA-mCherry vegetative cells in the gut of 756 
dogs #1 and #2, after oral application of three doses of recombinant B. subtilis spores 757 
(5x10
10
 CFU on days 1, 21 and 42). Each picture corresponds to open portions of 758 
representative sections of the duodenum, jejunum, ileum/cecum, and colon of each 759 
animal. A color luminescence scale is shown for each picture. All luminescent images 760 
were acquired with a Xenogen IVIS camera and analyzed using Living Image
®
 4.0 761 
software (Caliper Life Sciences, USA).  762 
Figure 3. Immune response after oral application in dogs of recombinant Bacillus 763 
subtilis tasA/sinR/lux/TasA-mCherry spores. Dogs sera, at the indicated days post-764 
application, were tested by indirect ELISA using plates coated with E. coli purified H6-765 
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mCherry (A), GST (B) and H6-TasA (C) and followed by incubation with specific anti-766 
IgG dog-HRP. The grey, white and black bars correspond to dogs #4, #5 and placebo, 767 
respectively. Dogs #4 and #5 were orally applied with recombinant Bacillus subtilis 768 
tasA/sinR/lux/TasA-mCherry spores. Placebo dog received only milk. The data represent 769 
the mean ± SEM of three independent experiments. D) Detection of E.coli purified H6-770 
mCherry by immunoblotting test stripes incubated with the indicated dog serum (diluted 771 
1:100) at day 60 post-application followed by incubation with specific anti-dog whole 772 
IgG-HRP. The positive control (+) (lane 1) was incubated with a specific mouse anti-773 
dsRed2 followed by anti-mouse-HRP. The arrow indicates the position of mCherry. E) 774 
Histological sections stained with hematoxylin and eosin from intestinal samples of dogs 775 
orally inoculated with recombinant B. subtilis spores (dogs #4 and #5) or placebo dog. 776 
Lm, intestinal lumen. Scale bar is 100µm. 777 
Figure 4.  A specific humoral response is elicited in dogs after oral application of 778 
recombinant B. subtilis spores harbouring Echinococcus granulosus antigens. Dog’s 779 
sera, at the indicated days post-application, were tested by indirect ELISA using plates 780 
coated with E. coli purified H6-EgTrp (A), H6-EgA31 (B), H6-mCherry (C) and H6-TasA 781 
(D). The samples were then incubated with a specific anti-IgG dog-HRP. The dog groups 782 
are indicated on the vertical axis. White and black bars correspond to the dogs #1 and #2 783 
of each group, respectively. The data represent the mean ± SEM of three independent 784 
experiments. E) Immunohistochemistry of sheep E. granulosus protoscoleces incubated 785 
with the indicated dogs sera (1:100) followed with secondary anti-IgG dog-HRP and 786 
stained with diaminobenzidine (brown). Nuclei were counterstained with hematoxylin 787 
(blue). Each row corresponds to the indicated the dog group (placebo, EgTrp, EgA31, and 788 
 o
n
 January 4, 2018 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://iai.asm
.org/
D
ow
nloaded from
 
 32 
 
mixture). The orally applied dog number is reported at the top of each panel. The right 789 
columns of the two panels correspond to enlargement insets of the indicated black frame 790 
at the left picture. The black arrows show the positive sera recognition of the 791 
protoscoleces subtegument/tegument membrane. Scale bar is 50 µm. F) PCR 792 
characterization of intestinal recombinant B. subtilis bacteria isolated from the small 793 
intestine of dog #2 from mixture group. Isolated colonies of one duodenum (D) and two 794 
jejuna (J1 and J2) sections were analyzed by PCR for the detection of B. subtilis 795 
tasA/sinR/TasA-EgTrp (upper panel) and B. subtilis tasA/sinR/TasA-EgTrp (lower panel) 796 
strains, respectively. In each panel, also included a set of controls namely EgTrp, EgA31 797 
and ∆T∆S which correspond to PCRs laboratory B. subtilis tasA/sinR/Tas-EgTrp, B. 798 
subtilis tasA/sinR/Tas-EgA31 and B. subtilis tasA/sinR strains, respectively. The yellow 799 
arrows indicated the position of each specific band. 800 
 801 
TABLES 802 
TABLE 1. B. subtilis strains used in this study. 803 
Strain Genotype
a
 Reference/source 
wt/lux lacA::PtasA-luxCDABE; Erm
R
 This study 
tasA/sinR/lux/TasA-
mCherry 
tasA::Km
R
;SinR::Spc
R
; 
lacA::PtasA-luxCDABE; 
MLS
R
; AmyE::yqxM-sipW-
tasA-mCherry ; Cm
R
 
This study 
tasA/sinR tasA-sinR::Km
R
 Vogt et al., 2016 (13) 
tasA/sinR/TasA-(102-
207)EgTrp 
tasA-sinR::Km
R
; 
amyE::yqxM-sipW-tasA-
(102-207)EgTrp; Spc
R
 
Vogt et al., 2016 (13) 
tasA/sinR/TasA-(370-
583)EgA31 
tasA-sinR::Km
R
; 
amyE::yqxM-sipW-tasA-
(370-583)EgA31; Spc
R
 
Vogt et al., 2016 (13) 
 o
n
 January 4, 2018 by UZH Hauptbibliothek / Zentralbibliothek Zuerich
http://iai.asm
.org/
D
ow
nloaded from
 
 33 
 
a
 Km
R
, kanamycin resistance gene; Spc
R
, spectinomycin resistance gene; Cm
R
, 
chloramphenicol resistance gene; MLS
R
, erythromycin and lincomycin gene 
resistances. 
 
TABLE 2. Dog identification number, gender, age and type of B. subtilis spore orally 804 
applied. 805 
Animal number Gender
e
 Age (weeks)
a
 B. subtilis spore strain
b
 
1,2 M, M 2 tasA/sinR/lux/TasA-mCherry 
3 F 9 Placebo
c
 
4, 5 M, F 9 tasA/sinR/lux/TasA-mCherry 
1, 2 F, M 9 Placebo
c
 
1, 2 M, F 9 tasA/sinR/TasA-(102-207)EgTrp 
1, 2 M, F 9 tasA/sinR/TasA-(370-583)EgA31 
1, 2 M, F 9 Mixture
d
 
a 
Age corresponding to the first B. subtilis spores received. 806 
b 
5x10
10
 CFU per dose of orally applied recombinant B. subtilis spores. 807 
c 
Milk 808 
d
2.5x10
10
 CFU tasA/sinR/TasA-(102-207)EgTrp and 2.5 x10
10
 CFU tasA/sinR/TasA(370-809 
583)EgA31 spores per dose. 810 
e 
F, female, and M, male. 811 
 812 
TABLE 3. Summary of the presence of recombinant spores of B. subtilis 813 
tasA/sinR/lux/TasA-mCherry strain in feces of dogs after the first and second oral 814 
applications. 815 
DPA
a
 
First oral application Second oral application 
 [#4]
b
  [#5] placebo  [#4]  [#5] placebo 
1
c
 - - - - - - 
2 +
d
 - - + - - 
3 - - - - - - 
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4 - - - - - - 
5 - - - - - - 
6 - - - - - - 
a 
DPA, days post-application 816 
b
 Dogs #4 and #5 were treated with 5x10
10
 CFU spores/dose of B. subtilis 817 
tasA/sinR/lux/TasA-mCherry strain diluted in milk and placebo was treated with milk 818 
only. 819 
c
 Samples obtained by anal swabs. 820 
d
The samples were considered positive (+) when resistant to heat treatment (80˚C for 20 821 
min) and displaying luminescence after germination, as inspected with an IVIS camera. 822 
 823 
TABLE 4. Presence and quantification of B. subtilis tasA/sinR/lux/TasA-mCherry spores 824 
in feces after a third oral application. 825 
DPAa 1 2 3 
RSb luminescencec sporesd luminescence spores luminescence spores 
1 
2 
3 
+ 
+ 
- 
2.4x105 
6.5x105 
nd 
+ 
- 
+ 
3.0x106 
nd 
1.7x105 
- 
+ 
_ 
nd 
1.3x104 
nd 
 826 
a
DPA, days post-application, and 
b
RS, random feces sample. 827 
cThe samples were considered positive (+) when resistant to heat treatment (80˚C for 20 828 
min) and displaying luminescence after germination, as inspected with an IVIS camera.
 829 
d
The number of recombinant B. subtilis spores is represented as the average of two 830 
independent measurements. The data corresponds to CFU per gram of feces. nd, not 831 
detected. 832 
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